BR112023018802A2 - Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação - Google Patents

Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação

Info

Publication number
BR112023018802A2
BR112023018802A2 BR112023018802A BR112023018802A BR112023018802A2 BR 112023018802 A2 BR112023018802 A2 BR 112023018802A2 BR 112023018802 A BR112023018802 A BR 112023018802A BR 112023018802 A BR112023018802 A BR 112023018802A BR 112023018802 A2 BR112023018802 A2 BR 112023018802A2
Authority
BR
Brazil
Prior art keywords
inflammation
long
growth hormone
treatment
acting growth
Prior art date
Application number
BR112023018802A
Other languages
English (en)
Inventor
Kennett Sprogøe
Jens Kjelgaard-Hansen Mads
Elisabeth Zois Nora
Tuxen Poulsen Thomas
Yang Yang-Malten
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of BR112023018802A2 publication Critical patent/BR112023018802A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação. a presente invenção refere-se a um hormônio de crescimento de ação prolongada (gh) para uso no tratamento de uma doença induzida por inflamação.
BR112023018802A 2021-04-01 2022-03-31 Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação BR112023018802A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21166699 2021-04-01
PCT/EP2022/058584 WO2022207798A1 (en) 2021-04-01 2022-03-31 Use of long-acting growth hormone for treating inflammation-induced diseases

Publications (1)

Publication Number Publication Date
BR112023018802A2 true BR112023018802A2 (pt) 2023-10-31

Family

ID=75362497

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018802A BR112023018802A2 (pt) 2021-04-01 2022-03-31 Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação

Country Status (10)

Country Link
EP (1) EP4314035A1 (pt)
JP (1) JP2024514095A (pt)
KR (1) KR20230164709A (pt)
CN (1) CN117396497A (pt)
AU (1) AU2022246997A1 (pt)
BR (1) BR112023018802A2 (pt)
CA (1) CA3212417A1 (pt)
IL (1) IL307192A (pt)
MX (1) MX2023011059A (pt)
WO (1) WO2022207798A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115845032A (zh) * 2022-10-28 2023-03-28 深圳科兴药业有限公司 生长激素fc融合蛋白注射液及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
DK1620118T3 (da) 2003-04-08 2014-09-29 Yeda Res & Dev Reversible pegylerede lægemidler
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
CA2693616A1 (en) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
US8906847B2 (en) 2008-02-01 2014-12-09 Ascendis Pharma A/S Prodrug comprising a drug linker conjugate
JP2011520983A (ja) 2008-05-23 2011-07-21 エンゾン ファーマシューティカルズ，インコーポレーテッド オリゴヌクレオチドの送達のための細胞内遊離可能ジスルフィドリンカーを含有するポリマーシステム
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
RU2554854C9 (ru) 2009-07-31 2017-02-03 Асцендис Фарма Ас Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
US8754190B2 (en) 2010-05-05 2014-06-17 Prolynx Llc Controlled release from macromolecular conjugates
US8946405B2 (en) 2010-05-05 2015-02-03 Prolynx Llc Controlled release from solid supports
EA024755B1 (ru) 2010-05-21 2016-10-31 ИксЭль-ПРОТЕИН ГМБХ Биосинтетические нерегулярные спиральные полипептиды пролина/аланина и их применения
AU2012296950B2 (en) 2011-08-12 2016-09-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
US20140323402A1 (en) 2011-08-12 2014-10-30 Ascendis Phama A/S Protein Carrier-Linked Prodrugs
US20140296257A1 (en) 2011-08-12 2014-10-02 Ascendis Pharma A/S High-Loading Water-Soluable Carrier-Linked Prodrugs
KR102226702B1 (ko) 2011-09-07 2021-03-11 프로린크스 엘엘시 생분해성 교차결합을 가지는 하이드로젤
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
WO2014056926A1 (en) 2012-10-11 2014-04-17 Ascendis Pharma A/S Hydrogel prodrugs
EP2908845A1 (en) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Fatty acid acylated amino acids for growth hormone delivery
CA2955569C (en) 2014-08-06 2023-02-14 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
CA2968282A1 (en) 2014-11-18 2016-05-26 Thomas Kurpiers Polymeric hgh prodrugs
AU2018240375C1 (en) 2017-03-22 2024-02-01 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
EP3856257A1 (en) 2018-09-26 2021-08-04 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
SG11202101971XA (en) 2018-09-26 2021-03-30 Ascendis Pharma As Novel hydrogel conjugates
BR112021020023A2 (pt) 2019-04-05 2021-12-07 Prolynx Llc Ligantes de conjugação melhorados
WO2021030196A1 (en) 2019-08-09 2021-02-18 Phasebio Pharmaceuticals, Inc. Elp fusion proteins comprising parathyroid hormone for controlled and sustained release

Also Published As

Publication number Publication date
IL307192A (en) 2023-11-01
AU2022246997A1 (en) 2023-09-28
EP4314035A1 (en) 2024-02-07
WO2022207798A1 (en) 2022-10-06
KR20230164709A (ko) 2023-12-04
MX2023011059A (es) 2023-09-29
CA3212417A1 (en) 2022-10-06
CN117396497A (zh) 2024-01-12
JP2024514095A (ja) 2024-03-28
AU2022246997A9 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
BR112017023233A2 (pt) métodos para tratamento de câncer
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
BRPI0511569A (pt) composições e métodos para o tratamento de distúrbio disfórico pré-menstrual
AR059982A1 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
CO2021006672A2 (es) Moduladores de nlrp3
GT200500028A (es) Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos.
BR112023018802A2 (pt) Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
BR112015022469A2 (pt) peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
CO2023018231A2 (es) Restos de administración terapéutica novedosos y usos de estos
CL2020002177A1 (es) Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparación y uso de las mismas
CL2021002483A1 (es) Compuestos y composiciones como moduladores de la señalización tlr
ECSP23077322A (es) Derivados de fósforo como nuevos inhibidores de sos1
CL2023001596A1 (es) Composiciones y métodos para el tratamiento de enfermedades oculares
CL2023000853A1 (es) Compuestos y composiciones como moduladores de señalización tlr
CO2022013429A2 (es) Formulaciones de liberación controlada que comprenden drotaverina o sal de la misma
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
ZA202001568B (en) Methods and compositions for treating chronic lung diseases